Health Care Equipment & Services

Explore Cigna Group’s latest market outlook: solid 16.3x P/E, rising Medicare Advantage share, and AI‑driven cost‑saving initiatives driving a stable, profitable health‑insurance profile.

Labcorp Holdings’ March 2026 update shows steady $273.61 stock price, $22 bn market cap and a 26.77 P/E, while its strategic shift into robotic phlebotomy, AI‑enabled diagnostics, and digital pathology positions it ahead of the 12‑15 % CAGR autonomo…

SHL’s share conversion and special dividend boost shareholder value and align employee interests, while the company drives cost‑control and margin growth across its global labs and imaging networks.

Veeva Systems’ Q2 2026 results show 23% revenue growth, a 30% net‑income rise, and a strong 5.8 billion‑dollar outlook, driven by its award‑winning Vault & CRM platform that speeds drug approvals and boosts data integrity for pharma and biotech.

Siemens Healthineers gets FDA clearance for its first dental MRI system, offering non‑radiation, high‑resolution imaging and AI‑powered workflow upgrades for better diagnostics and surgical planning.

Coloplast’s new CEO, Gavin Wood, faces U.S. reimbursement shifts while chasing €3bn growth under Impact 4, blending digital health, cost discipline and value‑based contracts to protect margins.

Pro Medicus secures $25 M U.S. contract renewals for Visage 7 Cardiology, boosting diagnostic accuracy, workflow efficiency and revenue for health systems.

Coloplast’s new CEO, Gavin Wood, is steering the Danish healthcare group toward digital innovation, tiered pricing, and value‑based reimbursement—boosting margins, expanding market share in chronic‑care and urology, and keeping debt low for sustaina…

Pro Medic’s new $40 M U.S. contracts boost revenue modestly, yet the real value lies in higher‑margin transaction fees, AI upsells and regulatory‑compliant edge—yet risks from customer concentration, tight regulations and fierce competition remain.

ResMed’s resilient stock, strong dividends, and new data‑driven CPAP tech position it to thrive in value‑based healthcare and grow sleep‑disordered breathing market share.